Clinical trials: Neoplasms of Prostate
Prostate Cancer
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
This is a phase I study to evaluate the feasibility and safety of using MRI/MRS to identify the dominant intraprostatic lesion (DIL) and to selectively boost the lesion using inverse planned high dose rate (HDR) brachytherapy.
- Trial name
- NCT00807820
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Metastatic Castration-resistant Prostate Cancer (mCRPC)
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC)…
- Trial name
- NCT07871435
- Testing
- GI-102, Pasritamig
- Where
- 6 sites in United States, South Korea
- Volunteers
- 107 people
- Sponsor
- GI Innovation, Inc.
Metastatic Hormone-Sensitive Prostate Cancer
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
This study study aims to elucidate the immune responses to a shared antigen vaccine (PROSTVAC) and tumor specific antigens generated DNA vaccine in combination with checkpoint blockade using nivolumab (anti-PD-1), and ipilimumab…
- Trial name
- NCT03532217
- Testing
- PROSTVAC-V, PROSTVAC-F, Nivolumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc
Prostatic Neoplasms
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
- Trial name
- NCT02234115
- Testing
- Leuprolide Mesylate
- Where
- 29 sites in United States, Austria and 6 more
- Volunteers
- 137 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Prostate Cancer, Prostate Cancer, Familial
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer, Familial, Hereditary Prostate Cancer
- Trial name
- NCT02381015
- Testing
- Genetic Risk Score: Number Format, Genetic Risk Score: Number + Pictograph, Family History: Number Format
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Metastatic Prostate Cancer
68Ga-PSMA PET/CT for Ra223 Assessment
Primary objective: i.The primary objective is to compare the diagnostic positivity in progression of 68Ga-PSMA PET and Bone scan.
- Trial name
- NCT04951817
- Testing
- Ga-68 PSMA ligand
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Neoplasm
Role of Soy Supplementation in Prostate Cancer Development
This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue.
- Trial name
- NCT00255125
- Testing
- Soy Supplement
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- VA Office of Research and Development
Recurrent Prostate Cancer
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
For the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT)
- Trial name
- STAR (NCT00772317)
- Testing
- High Intensity Focused Ultrasound
- Where
- 16 sites in United States, Canada
- Volunteers
- 117 people
- Sponsor
- SonaCare Medical
Prostate Cancer
Prostate Imaging Using MRI +/- Contrast Enhancement
This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically…
- Trial name
- PRIME (NCT04571840)
- Testing
- Multiparametric MRI +/- prostate biopsy, Biparametric MRI +/- prostate biopsy
- Where
- 31 sites in United States, Argentina and 13 more
- Volunteers
- 500 people
- Sponsor
- University College, London
Cancer, Prostate Cancers
Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada
EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC).
- Conditions
- Cancer, Prostate Cancers, Breast Cancers, Colon Cancer
- Trial name
- EXCEL (NCT06960291)
- Testing
- Group Exercise Classes
- Where
- 5 sites in Canada
- Volunteers
- 740 people
- Sponsor
- University of Calgary
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Prostate Cancer
Training on Systemic and Organ Spec. PM in PC
This research is being done to assess the impact of a supervised and structured strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation…
- Trial name
- NCT07768917
- Testing
- Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Bone Metastases
Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
The goal of this clinical trial was to assess the diagnostic performance and safety of Sodium Fluoride F-18 Positron Emission Tomography / Computed Tomography (18F-NaF-PET/CT) in bone metastases of malignant tumors compared with…
- Trial name
- NCT05614518
- Testing
- Sodium Fluoride F-18 Injection, Technetium[99mTc] Methylenediphosphonate Injection
- Where
- China
- Volunteers
- 280 people
- Sponsor
- HTA Co., Ltd.
Prostate Cancer, Localized Prostate Cancer
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
This study investigates the pathologic effects of the combination of enzalutamide, abiraterone acetate, dutasteride, and degarelix when given for 12 weeks prior to prostatectomy in men with localized prostate cancer.
- Trial name
- NCT02159690
- Testing
- Enzalutamide, Abiraterone acetate, Prednisone
- Where
- United States
- Sponsor
- Kenneth Pienta, MD
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Personalized Mini-PDX for Metastatic CRPC
The investigators intend to use the Second-generation sequencing（NGS）and MiniPDX drug sensitivity models to guide the treatment decision-making for patients who were resistant to abiraterone, enzalutamide or other new…
- Trial name
- NCT03786848
- Testing
- MiniPDX Group
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Second Hospital
Metastatic Breast Cancer, Colorectal Cancer
Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT02020291
- Testing
- Foxy-5
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- WntResearch AB
Prostate Cancer (Adenocarcinoma)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach…
- Trial name
- TRIPLE-SWITCH (NCT06592924)
- Testing
- Abiraterone, Enzalutamide, Apalutamide
- Where
- 395 sites in United States, Canada and 2 more
- Volunteers
- 830 people
- Sponsor
- Canadian Cancer Trials Group